Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 4(4): e5046, 2009.
Article in English | MEDLINE | ID: mdl-19352491

ABSTRACT

BACKGROUND: Developmental, physiological and tissue engineering studies critical to the development of successful myocardial regeneration therapies require new ways to effectively visualize and isolate large numbers of fluorescently labeled, functional cardiomyocytes. METHODOLOGY/PRINCIPAL FINDINGS: Here we describe methods for the clonal expansion of engineered hESCs and make available a suite of lentiviral vectors for that combine Blasticidin, Neomycin and Puromycin resistance based drug selection of pure populations of stem cells and cardiomyocytes with ubiquitous or lineage-specific promoters that direct expression of fluorescent proteins to visualize and track cardiomyocytes and their progenitors. The phospho-glycerate kinase (PGK) promoter was used to ubiquitously direct expression of histone-2B fused eGFP and mCherry proteins to the nucleus to monitor DNA content and enable tracking of cell migration and lineage. Vectors with T/Brachyury and alpha-myosin heavy chain (alphaMHC) promoters targeted fluorescent or drug-resistance proteins to early mesoderm and cardiomyocytes. The drug selection protocol yielded 96% pure cardiomyocytes that could be cultured for over 4 months. Puromycin-selected cardiomyocytes exhibited a gene expression profile similar to that of adult human cardiomyocytes and generated force and action potentials consistent with normal fetal cardiomyocytes, documenting these parameters in hESC-derived cardiomyocytes and validating that the selected cells retained normal differentiation and function. CONCLUSION/SIGNIFICANCE: The protocols, vectors and gene expression data comprise tools to enhance cardiomyocyte production for large-scale applications.


Subject(s)
Embryonic Stem Cells/cytology , Genetic Vectors , Lentivirus/genetics , Myocardium/cytology , Adult , Base Sequence , Cell Differentiation , DNA Primers , Drug Resistance , Embryonic Stem Cells/metabolism , Fetal Proteins/genetics , Flow Cytometry , Gene Expression Profiling , Green Fluorescent Proteins/genetics , Humans , Immunohistochemistry , Myocardium/metabolism , Promoter Regions, Genetic , Reverse Transcriptase Polymerase Chain Reaction , T-Box Domain Proteins/genetics
2.
J Cell Biol ; 183(1): 129-41, 2008 Oct 06.
Article in English | MEDLINE | ID: mdl-18838555

ABSTRACT

The inability of heart muscle to regenerate by replication of existing cardiomyocytes has engendered considerable interest in identifying developmental or other stimuli capable of sustaining the proliferative capacity of immature cardiomyocytes or stimulating division of postmitotic cardiomyocytes. Here, we demonstrate that reactivation of Notch signaling causes embryonic stem cell-derived and neonatal ventricular cardiomyocytes to enter the cell cycle. The proliferative response of neonatal ventricular cardiomyocytes declines as they mature, such that late activation of Notch triggers the DNA damage checkpoint and G2/M interphase arrest. Notch induces recombination signal-binding protein 1 for Jkappa (RBP-Jkappa)-dependent expression of cyclin D1 but, unlike other inducers, also shifts its subcellular distribution from the cytosol to the nucleus. Nuclear localization of cyclin D1 is independent of RBP-Jkappa. Thus, the influence of Notch on nucleocytoplasmic localization of cyclin D1 is an unanticipated property of the Notch intracellular domain that is likely to regulate the cell cycle in multiple contexts, including tumorigenesis as well as cardiogenesis.


Subject(s)
Cell Cycle/physiology , Myocytes, Cardiac/metabolism , Receptors, Notch/physiology , Active Transport, Cell Nucleus , Animals , Animals, Newborn , Apoptosis/drug effects , Basic Helix-Loop-Helix Transcription Factors/genetics , Basic Helix-Loop-Helix Transcription Factors/metabolism , CDC2 Protein Kinase/metabolism , Caffeine/pharmacology , Cell Cycle/drug effects , Cell Nucleus/metabolism , Cell Proliferation , Cells, Cultured , Cyclin D1/metabolism , Glycogen Synthase Kinase 3/metabolism , Glycogen Synthase Kinase 3 beta , Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Immunoglobulin J Recombination Signal Sequence-Binding Protein/genetics , Immunoglobulin J Recombination Signal Sequence-Binding Protein/metabolism , Mice , Models, Biological , Myocytes, Cardiac/cytology , Phosphorylation , Rats , Rats, Sprague-Dawley , Receptor, Notch2/physiology , Retinoblastoma Protein/metabolism , Time Factors , Transcription Factor HES-1 , Transfection
3.
Nat Med ; 12(3): 310-6, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16491084

ABSTRACT

The nature and even existence of adult pancreatic endocrine stem or progenitor cells is a subject of controversy in the field of beta-cell replacement for diabetes. One place to search for such cells is in the nonendocrine fraction of cells that remain after islet isolation, which consist of a mixture of epithelia and mesenchyme. Culture in G418 resulted in elimination of the mesenchymal cells, leaving a highly purified population of nonendocrine pancreatic epithelial cells (NEPECs). To evaluate their differentiation potential, NEPECs were heritably marked and transplanted under the kidney capsule of immunodeficient mice. When cotransplanted with fetal pancreatic cells, NEPECs were capable of endocrine differentiation. We found no evidence of beta-cell replication or cell fusion that could have explained the appearance of insulin positive cells from a source other than NEPECs. Nonendocrine-to-endocrine differentiation of NEPECs supports the existence of endocrine stem or progenitor cells within the epithelial compartment of the adult human pancreas.


Subject(s)
Cell Differentiation , Epithelial Cells/cytology , Islets of Langerhans/cytology , Adult , Animals , Cell Fusion , Cell Transplantation , Cell- and Tissue-Based Therapy , Cells, Cultured , DNA Replication , Epithelial Cells/metabolism , Fetus/cytology , Gentamicins/pharmacology , Humans , Insulin/metabolism , Islets of Langerhans/metabolism , Mesoderm/cytology , Mesoderm/drug effects , Mice , Mice, SCID , Middle Aged
4.
Nat Genet ; 32(4): 670-5, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12426566

ABSTRACT

Dystrophic epidermolysis bullosa (DEB) is a family of inherited mechano-bullous disorders caused by mutations in the human type VII collagen gene (COL7A1). Individuals with DEB lack type VII collagen and anchoring fibrils, structures that attach epidermis and dermis. The current lack of treatment for DEB is an impetus to develop gene therapy strategies that efficiently transfer and stably express genes delivered to skin cells in vivo. In this study, we delivered and expressed full-length type VII collagen using a self-inactivating minimal lentivirus-based vector. Transduction of lentiviral vectors containing the COL7A1 transgene into recessive DEB (RDEB) keratinocytes and fibroblasts (in which type VII collagen was absent) resulted in persistent synthesis and secretion of type VII collagen. Unlike RDEB parent cells, the gene-corrected cells had normal morphology, proliferative potential, matrix attachment and motility. We used these gene-corrected cells to regenerate human skin on immune-deficient mice. Human skin regenerated by gene-corrected RDEB cells had restored expression of type VII collagen and formation of anchoring fibrils at the dermal-epidermal junction in vivo. These studies demonstrate that it is possible to restore type VII collagen gene expression in RDEB skin in vivo.


Subject(s)
Collagen Type VII/genetics , Collagen Type VII/physiology , Epidermolysis Bullosa Dystrophica/metabolism , Cell Adhesion , Cell Division , Cell Line , Cell Movement , Cell Transformation, Viral , Cells, Cultured , Collagen Type VII/biosynthesis , DNA, Complementary , Epidermal Cells , Epidermolysis Bullosa Dystrophica/genetics , Epidermolysis Bullosa Dystrophica/therapy , Fibroblasts/metabolism , Fibroblasts/pathology , Fibroblasts/ultrastructure , Gene Transfer Techniques , Genes, Recessive , Genetic Therapy , Genetic Vectors , Humans , Keratinocytes/metabolism , Keratinocytes/pathology , Keratinocytes/ultrastructure , Laminin/metabolism , Lentivirus/genetics , Mutation , Transfection , Transgenes
SELECTION OF CITATIONS
SEARCH DETAIL
...